High burden of blaKPC-2-positive carbapenem-resistant Klebsiella pneumoniae among inpatients in a Tertiary Care Hospital in Kathmandu.
OBJECTIVE Klebsiella pneumoniae, a major nosocomial pathogen, is increasingly associated with multidrug resistance and carbapenem production, posing a significant therapeutic challenge on a global scale. The study aimed to determine the distribution, antimicrobial susceptibility pattern, and molecular identification of blaKPC-2 and blaVIM genes among carbapenem-resistant K. pneumoniae isolated from clinical specimens. METHODS Between January and June 2024, a hospital-based cross-sectional study was carried out at Kirtipur Hospital in Nepal. Standard microbiological protocols were adopted for the processing of 5002 clinical samples. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method following CLSI guidelines. The modified carbapenem inactivation method (mCIM) and the EDTA-modified carbapenem inactivation method (eCIM) were used to confirm carbapenemase production phenotypically, and the polymerase chain reaction (PCR) was used to detect the blaKPC-2 and blaVIM genes at the molecular level. RESULTS Of the total samples, 18.3% (917) showed bacterial growth, with K. pneumoniae accounting for 7.6% (n = 70) of isolates, predominantly from wound/pus (35.7%), urine (32.8%), and blood (17.1%) specimens. High resistance was observed against imipenem (68.6%), ceftazidime (64.3%), and ceftriaxone (62.9%), whereas tigecycline and doxycycline remained the most effective ones. Twelve (30.8%) of the 39 carbapenem-resistant isolates were determined to be carbapenemases producers, all harboring blaKPC-2 (100%) and three (25%) additionally carrying blaVIM. CONCLUSION The dominance of KPC-mediated resistance among the hospitalized patients, underscores the need for rigorous infection control, ongoing molecular surveillance, and prudent antimicrobial stewardship to stop the spread of high-risk K. pneumoniae strains in healthcare environments.